Technical breakthrough · 09. April 2021
To address all B cell depletion needs, SYnAbs has developed monoclonal antibody references, which exhibit the ability to deplete murine or rat B cells in vivo, providing a valuable research tool for its biotech and pharma partners.
Technical breakthrough · 19. March 2021
SYnAbs enters in a strategic agreement with Volition to generate monoclonal antibodies against epigenetics biomarkers including modifications of histones and DNA, histone variants, and proteins associated with nucleosomes
Technical breakthrough · 08. March 2021
How to generate effective neutralizing antibodies to target infectious disease transmembrane protein antigens. A review of the technical challenges, strategies, and risks.
Technical breakthrough · 20. February 2021
SYnabs generate anti-drug antibodies for small molecules and therapeutic antibodies. Paratope-specific anti-idiotype antibodies, non-inhibitory anti-idiotype antibodies, or drug-target complex binders generation.
Technical breakthrough · 25. January 2021
SYnAbs develops therapeutic effector monoclonal antibodies against ion channel transmembrane proteins thanks to DNA and cell immunization technologies
Technical breakthrough · 11. January 2021
From Galvani' spark to the three-dimensional structure of ion channels, learn the fabulous history of unique transmembrane proteins
Technical breakthrough · 14. December 2020
Molecular dynamics of G protein-coupled receptors (GPCRs) and unique monoclonal antibody effectors and binders targeting GPCR.
Technical breakthrough · 28. November 2020
SYnAbs unique anti-androstanolone (anti-DHT) monoclonal antibodies of a pg sensitivity level and no cross-reactivity to free testosterone
Technical breakthrough · 14. November 2020
SYnAbs develops immuno-affinity columns to purify rat, mouse antibodies in serum culture conditions with high specificity and develops custom immuno-affinity columns on demand
Technical breakthrough · 06. November 2020
SYnAbs offers recombinant polyclonal antibodies production, oligoclonal and multiclonal antibody cocktails